Combination and augmentation strategies in treatment-resistant schizophrenia

Treatment resistance in schizophrenia puts guideline-recommended monotherapy to a challenge, and polypharmacy is used to address treatment-refractory psychotic features, affective symptoms, cognitive impairment, secondary obsessive–compulsive syndromes and treatment-emergent side effects caused by a...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today. Therapeutic strategies 2011-06, Vol.8 (1), p.17-23
Main Authors: Englisch, Susanne, Zink, Mathias
Format: Article
Language:English
Subjects:
Medical Education
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment resistance in schizophrenia puts guideline-recommended monotherapy to a challenge, and polypharmacy is used to address treatment-refractory psychotic features, affective symptoms, cognitive impairment, secondary obsessive–compulsive syndromes and treatment-emergent side effects caused by antipsychotics. Hereunto, both combinations of different antipsychotic agents and augmentation with mood stabilizers, antidepressants and experimental substances are applied. This review will discuss risks, benefits and levels of evidence of combination strategies involving multiple psychotropic substances, with a focus on their clinical relevance.
ISSN:1740-6773
1740-6773
DOI:10.1016/j.ddstr.2011.09.002